Johnson & Johnson's ERLEADA® (apalutamide) Reduces Prostate Cancer Recurrence Risk by 62% in High-Risk Patients

New results from the Phase 3 PROTEUS substudy show that treatment with apalutamide plus hormone therapy, administered for six months before and after surgery, significantly reduced the risk of disease recurrence or death by 62% compared to surgery alone in patients with high-risk localized or locally advanced prostate cancer. The data was presented at the European Society for Medical Oncology (ESMO) 2026 Congress.